You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameConivaptan
Accession NumberDB00872  (APRD01302)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionConivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Structure
Thumb
Synonyms
4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Conivaptan
External Identifiers
  • YM 087
  • YM-087
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vaprisol Dextrose In Plastic ContainerInjection, solution20 mg/100mLIntravenousCumberland Pharmaceuticals Inc.2008-10-08Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VaprisolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Conivaptan hydrochloride
Thumb
  • InChI Key: BTYHAFSDANBVMJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 534.182253835
  • Average Mass: 535.035
DBSALT000793
Categories
UNII0NJ98Y462X
CAS number210101-16-9
WeightAverage: 498.5744
Monoisotopic: 498.205576096
Chemical FormulaC32H26N4O2
InChI KeyIKENVDNFQMCRTR-UHFFFAOYSA-N
InChI
InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
IUPAC Name
N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2(6),3,10,12-pentaene-9-carbonyl}phenyl)-2-phenylbenzamide
SMILES
CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1
Pharmacology
IndicationFor the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
Structured Indications
PharmacodynamicsConivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range by increasing permeability of the renal collecting ducts to water. Vasopressin also causes vasoconstriction through its actions on vascular 1A receptors. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. Conivaptan's antagonist activity on V1A receptors may also cause splanchnic vasodilation, resulting in possible hypotension or variceal bleeding in patients with cirrhosis. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.
Mechanism of actionConivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water.
TargetKindPharmacological actionActionsOrganismUniProt ID
Vasopressin V1a receptorProteinyes
antagonist
HumanP37288 details
Vasopressin V2 receptorProteinyes
antagonist
HumanP30518 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding99%
Metabolism

CYP3A4 is the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan. Four metabolites have been identified. The pharmacological activity of the metabolites at V1a and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.

Route of eliminationNot Available
Half life5 hours
ClearanceNot Available
ToxicityAlthough no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Conivaptan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Conivaptan can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Conivaptan.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Conivaptan.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Conivaptan.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Conivaptan.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Acetazolamide.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Conivaptan.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Conivaptan.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Conivaptan.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Conivaptan.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Conivaptan.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Conivaptan.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Conivaptan.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Conivaptan.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Conivaptan.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Conivaptan.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Conivaptan.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Conivaptan.Experimental, Illicit
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Conivaptan.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Conivaptan.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Conivaptan.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Conivaptan.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Conivaptan.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Conivaptan.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Conivaptan.Approved
AmiodaroneThe serum concentration of Conivaptan can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Conivaptan.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Conivaptan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Conivaptan.Approved, Illicit
AmorolfineThe metabolism of Conivaptan can be decreased when combined with Amorolfine.Approved
Amphotericin BThe metabolism of Conivaptan can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Conivaptan.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Conivaptan.Approved
AN2690The metabolism of Conivaptan can be decreased when combined with AN2690.Investigational
AnidulafunginThe metabolism of Conivaptan can be decreased when combined with Anidulafungin.Approved, Investigational
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Conivaptan.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Conivaptan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Conivaptan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Conivaptan.Approved
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Conivaptan.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Conivaptan.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Conivaptan.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Conivaptan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Conivaptan.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Conivaptan.Approved, Investigational
ArtemetherThe metabolism of Conivaptan can be decreased when combined with Artemether.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Conivaptan.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Conivaptan.Approved, Withdrawn
AtazanavirThe serum concentration of Conivaptan can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Conivaptan.Approved
AtomoxetineThe metabolism of Conivaptan can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Conivaptan.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Conivaptan.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Conivaptan.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Conivaptan.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Conivaptan.Approved
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Conivaptan.Approved
Bafilomycin A1The metabolism of Conivaptan can be decreased when combined with Bafilomycin A1.Experimental
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Conivaptan.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Conivaptan.Experimental
BarbitalBarbital may increase the hypotensive activities of Conivaptan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Conivaptan.Approved
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Conivaptan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Conivaptan.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Conivaptan.Approved
Benzoic AcidThe metabolism of Conivaptan can be decreased when combined with Benzoic Acid.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Conivaptan.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Conivaptan.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Conivaptan.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Conivaptan.Approved
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Conivaptan.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Conivaptan.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Conivaptan.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Conivaptan.Approved
BifonazoleThe metabolism of Conivaptan can be decreased when combined with Bifonazole.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Conivaptan.Approved
BoceprevirThe serum concentration of Conivaptan can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Conivaptan.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Conivaptan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Conivaptan.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Conivaptan.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Conivaptan.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Conivaptan.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Conivaptan.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Conivaptan.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Conivaptan.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Conivaptan.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Conivaptan.Approved
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Conivaptan.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Conivaptan.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Conivaptan.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Conivaptan.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Conivaptan.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Conivaptan.Approved, Investigational
ButenafineThe metabolism of Conivaptan can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Conivaptan can be decreased when combined with Butoconazole.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Conivaptan.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Conivaptan.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Conivaptan.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Conivaptan.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Conivaptan.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Conivaptan.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Conivaptan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Conivaptan.Approved
CandicidinThe metabolism of Conivaptan can be decreased when combined with Candicidin.Withdrawn
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Conivaptan.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Conivaptan.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Conivaptan.Approved
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Conivaptan.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Conivaptan.Illicit, Vet Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Conivaptan.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Conivaptan.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Conivaptan.Approved, Investigational
CaspofunginThe metabolism of Conivaptan can be decreased when combined with Caspofungin.Approved
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Conivaptan.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Conivaptan.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Conivaptan.Approved, Vet Approved
CeritinibThe serum concentration of Conivaptan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Conivaptan.Withdrawn
CeruleninThe metabolism of Conivaptan can be decreased when combined with Cerulenin.Approved
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Conivaptan.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Conivaptan.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Conivaptan.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Conivaptan.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Conivaptan.Approved, Vet Approved
ChloroxineThe metabolism of Conivaptan can be decreased when combined with Chloroxine.Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Conivaptan.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Conivaptan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Conivaptan.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Conivaptan.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Conivaptan.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Conivaptan.Approved, Investigational
CiclopiroxThe metabolism of Conivaptan can be decreased when combined with Ciclopirox.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Conivaptan.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Conivaptan.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Conivaptan.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Conivaptan.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Conivaptan.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Conivaptan.Approved
ClarithromycinThe serum concentration of Conivaptan can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Conivaptan can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Conivaptan.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Conivaptan.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Conivaptan.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Conivaptan.Approved, Investigational
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Conivaptan.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Conivaptan.Approved
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Conivaptan.Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Conivaptan.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Conivaptan.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Conivaptan.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Conivaptan.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Conivaptan.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Conivaptan.Approved, Illicit
ClotrimazoleThe metabolism of Conivaptan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Conivaptan.Approved
CobicistatThe serum concentration of Conivaptan can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Conivaptan.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Conivaptan.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Conivaptan.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Conivaptan.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Conivaptan.Approved
CordycepinThe metabolism of Conivaptan can be decreased when combined with Cordycepin.Investigational
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Conivaptan.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Conivaptan.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Conivaptan.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Conivaptan.Approved, Investigational
CyclosporineThe metabolism of Conivaptan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Conivaptan.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Conivaptan.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Conivaptan.Approved
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Conivaptan.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Conivaptan.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Conivaptan.Investigational
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Conivaptan.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Conivaptan.Approved, Investigational
DarunavirThe serum concentration of Conivaptan can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Conivaptan.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Conivaptan.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Conivaptan.Approved
Decanoic AcidThe metabolism of Conivaptan can be decreased when combined with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Conivaptan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Conivaptan.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Desflurane.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Conivaptan.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Conivaptan.Approved, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Conivaptan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Conivaptan.Experimental, Illicit
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Conivaptan.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Conivaptan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Conivaptan.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Conivaptan.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Conivaptan.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Conivaptan.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Conivaptan.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Conivaptan.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Conivaptan.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Conivaptan.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Conivaptan.Experimental, Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Conivaptan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Conivaptan.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Conivaptan.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Conivaptan.Approved
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Conivaptan.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Conivaptan.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Conivaptan.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Conivaptan.Approved
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Conivaptan.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Conivaptan.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Conivaptan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Conivaptan.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Conivaptan.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Conivaptan.Approved, Investigational
DoxycyclineThe metabolism of Conivaptan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Conivaptan.Investigational
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Conivaptan.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Conivaptan.Approved
DuloxetineConivaptan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Conivaptan.Approved, Investigational
EconazoleThe metabolism of Conivaptan can be decreased when combined with Econazole.Approved
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Conivaptan.Approved, Investigational
EfinaconazoleThe metabolism of Conivaptan can be decreased when combined with Efinaconazole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Conivaptan.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Conivaptan.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Conivaptan.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Conivaptan.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Conivaptan.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Conivaptan is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Conivaptan.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Conivaptan.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Conivaptan.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Conivaptan is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Conivaptan.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Conivaptan.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Conivaptan.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Conivaptan.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Conivaptan.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Conivaptan.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Conivaptan.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Conivaptan.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Conivaptan can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Conivaptan.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Conivaptan.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Conivaptan.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Conivaptan.Approved
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Conivaptan.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Conivaptan.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Conivaptan.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Conivaptan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Conivaptan.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Conivaptan.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Conivaptan.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Conivaptan.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Conivaptan.Approved, Illicit
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Conivaptan.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Conivaptan.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Conivaptan.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Conivaptan.Illicit, Vet Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Conivaptan.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Conivaptan.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Conivaptan.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Conivaptan.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Conivaptan.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Conivaptan.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Conivaptan.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Conivaptan.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Conivaptan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fimasartan.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Conivaptan.Approved
FingolimodThe serum concentration of Fingolimod can be increased when it is combined with Conivaptan.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Conivaptan.Approved
FluconazoleThe metabolism of Conivaptan can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Conivaptan can be decreased when combined with Flucytosine.Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Conivaptan.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Conivaptan.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Conivaptan.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Conivaptan.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Conivaptan.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Conivaptan.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Conivaptan.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Conivaptan.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Conivaptan.Approved
FluvoxamineThe metabolism of Conivaptan can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Conivaptan.Approved
FosaprepitantThe serum concentration of Conivaptan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Conivaptan.Approved
FosphenytoinThe metabolism of Conivaptan can be increased when combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Conivaptan.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Conivaptan.Approved, Vet Approved
Fusidic AcidThe serum concentration of Conivaptan can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Conivaptan.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Conivaptan.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Conivaptan.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Conivaptan.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Conivaptan.Approved
GlyphosateThe metabolism of Conivaptan can be decreased when combined with Glyphosate.Experimental
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Conivaptan.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Conivaptan.Withdrawn
GriseofulvinThe metabolism of Conivaptan can be decreased when combined with Griseofulvin.Approved, Vet Approved
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Conivaptan.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Conivaptan.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Conivaptan.Approved
HaloproginThe metabolism of Conivaptan can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe serum concentration of Halothane can be increased when it is combined with Conivaptan.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Conivaptan.Approved, Illicit
HexetidineThe metabolism of Conivaptan can be decreased when combined with Hexetidine.Approved
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Conivaptan.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Conivaptan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Conivaptan.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Conivaptan.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Conivaptan.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Conivaptan.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydroflumethiazide.Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Conivaptan.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Conivaptan.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Conivaptan.Approved
IdelalisibThe serum concentration of Conivaptan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Conivaptan.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Conivaptan.Approved
IloprostThe risk or severity of adverse effects can be increased when Conivaptan is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Conivaptan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Conivaptan.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Conivaptan.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Conivaptan.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Conivaptan.Approved
IndinavirThe serum concentration of Conivaptan can be increased when it is combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Conivaptan is combined with Indoramin.Withdrawn
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Conivaptan.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Conivaptan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Conivaptan.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Conivaptan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isocarboxazid.Approved
IsoconazoleThe metabolism of Conivaptan can be decreased when combined with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Conivaptan.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Conivaptan.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Conivaptan.Approved, Withdrawn
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Conivaptan.Approved
ItraconazoleThe serum concentration of Conivaptan can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Conivaptan.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Conivaptan.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Conivaptan.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Conivaptan.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Conivaptan.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Conivaptan.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Conivaptan.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Conivaptan.Approved
KetoconazoleThe serum concentration of Conivaptan can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Conivaptan.Approved
LacidipineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Lacidipine.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Conivaptan.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Conivaptan.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Conivaptan.Investigational
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Conivaptan.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Conivaptan.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Conivaptan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Conivaptan.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Conivaptan.Approved
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Conivaptan.Approved
LevodopaConivaptan may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Conivaptan.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Conivaptan.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Conivaptan.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Conivaptan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Conivaptan.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Conivaptan.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Conivaptan.Approved, Investigational
LisurideThe serum concentration of Lisuride can be increased when it is combined with Conivaptan.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Conivaptan.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Conivaptan.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Conivaptan.Approved
LopinavirThe serum concentration of Conivaptan can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Conivaptan.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Conivaptan.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Conivaptan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Conivaptan.Approved, Investigational
LuliconazoleThe serum concentration of Conivaptan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Conivaptan can be increased when combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Conivaptan.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Conivaptan.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Conivaptan.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Conivaptan.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Conivaptan.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Conivaptan.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Conivaptan.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Conivaptan.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Conivaptan.Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Conivaptan.Approved, Vet Approved
MethadoneThe serum concentration of Methadone can be increased when it is combined with Conivaptan.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Conivaptan.Approved, Illicit
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Conivaptan.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Conivaptan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Conivaptan.Approved
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Conivaptan.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Conivaptan.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Conivaptan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Conivaptan.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Conivaptan.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Conivaptan.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Conivaptan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Conivaptan.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Conivaptan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Conivaptan.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Conivaptan.Approved
MevastatinThe metabolism of Conivaptan can be decreased when combined with Mevastatin.Experimental
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Conivaptan.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Conivaptan.Approved
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Conivaptan.Withdrawn
MicafunginThe metabolism of Conivaptan can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Conivaptan can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Conivaptan.Approved, Illicit
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Conivaptan.Approved, Investigational
MiltefosineThe metabolism of Conivaptan can be decreased when combined with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Conivaptan.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Conivaptan.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Conivaptan.Approved
MitotaneThe serum concentration of Conivaptan can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Conivaptan.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Conivaptan.Approved
MonensinThe metabolism of Conivaptan can be decreased when combined with Monensin.Vet Approved
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Conivaptan.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Conivaptan.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Conivaptan.Approved, Investigational
MyxothiazolThe metabolism of Conivaptan can be decreased when combined with Myxothiazol.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Conivaptan.Approved
NafcillinThe serum concentration of Conivaptan can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Conivaptan can be decreased when combined with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Conivaptan.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Conivaptan.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Conivaptan.Approved, Vet Approved
NatamycinThe metabolism of Conivaptan can be decreased when combined with Natamycin.Approved
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Conivaptan.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Conivaptan.Approved, Investigational
NefazodoneThe serum concentration of Conivaptan can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Conivaptan can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Conivaptan.Approved, Investigational
NetupitantThe serum concentration of Conivaptan can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Conivaptan.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Conivaptan.Approved
NicorandilNicorandil may increase the hypotensive activities of Conivaptan.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Conivaptan.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Conivaptan.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Conivaptan.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Conivaptan.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Conivaptan.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Conivaptan.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Conivaptan.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Conivaptan.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Conivaptan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Conivaptan.Approved
NitroxolineThe metabolism of Conivaptan can be decreased when combined with Nitroxoline.Approved
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Conivaptan.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Conivaptan.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Conivaptan.Approved, Illicit
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Conivaptan.Approved
NystatinThe metabolism of Conivaptan can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Conivaptan is combined with Obinutuzumab.Approved
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Conivaptan.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Conivaptan.Approved, Investigational
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Conivaptan.Approved
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Conivaptan.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Conivaptan.Approved, Illicit
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Conivaptan.Approved
OsimertinibThe serum concentration of Conivaptan can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Conivaptan.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Conivaptan.Approved
OxiconazoleThe metabolism of Conivaptan can be decreased when combined with Oxiconazole.Approved
OxprenololThe risk or severity of adverse effects can be increased when Conivaptan is combined with Oxprenolol.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Conivaptan.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Conivaptan.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.Approved, Vet Approved
pafuramidineThe metabolism of Conivaptan can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Conivaptan.Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Conivaptan.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Conivaptan.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Conivaptan.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Conivaptan.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Conivaptan.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Conivaptan.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Conivaptan.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Conivaptan.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Conivaptan.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Conivaptan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Conivaptan.Approved, Investigational
PentamidineThe metabolism of Conivaptan can be decreased when combined with Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.Approved, Vet Approved
PentobarbitalThe metabolism of Conivaptan can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Conivaptan.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Conivaptan.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Conivaptan.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Conivaptan.Approved
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Conivaptan.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Conivaptan.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Conivaptan.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Conivaptan.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Conivaptan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Conivaptan.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Conivaptan.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Conivaptan.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Conivaptan.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Conivaptan.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Conivaptan.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Conivaptan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Conivaptan.Approved
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Conivaptan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pipamperone.Approved
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Conivaptan.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Conivaptan.Investigational
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Conivaptan.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Conivaptan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Conivaptan.Approved
PosaconazoleThe serum concentration of Conivaptan can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pramipexole.Approved, Investigational
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Conivaptan.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Conivaptan.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Conivaptan.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Conivaptan.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Conivaptan.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Conivaptan.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Conivaptan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Conivaptan.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Conivaptan.Approved
PrimidoneThe metabolism of Conivaptan can be increased when combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Conivaptan.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Conivaptan.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Conivaptan.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Conivaptan.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Conivaptan.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Conivaptan.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Conivaptan.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Conivaptan.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Conivaptan.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Conivaptan.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Conivaptan.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Conivaptan.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Conivaptan.Approved
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Conivaptan.Approved, Investigational
RadicicolThe metabolism of Conivaptan can be decreased when combined with Radicicol.Experimental
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Conivaptan.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Conivaptan.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Conivaptan.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Conivaptan.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Conivaptan.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Conivaptan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Conivaptan.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Conivaptan.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Conivaptan.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Conivaptan.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Conivaptan.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Conivaptan.Approved
RifapentineThe metabolism of Conivaptan can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Conivaptan.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Conivaptan.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Conivaptan.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Conivaptan.Approved, Investigational
RitonavirThe serum concentration of Conivaptan can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Conivaptan.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Conivaptan.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Conivaptan.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Conivaptan.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Conivaptan.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Conivaptan.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Conivaptan.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Conivaptan.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Conivaptan.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Conivaptan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Conivaptan is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe metabolism of Conivaptan can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Conivaptan can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Conivaptan.Approved
SaquinavirThe serum concentration of Conivaptan can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Conivaptan.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Conivaptan.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Conivaptan.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Conivaptan.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Conivaptan.Approved, Investigational
SertaconazoleThe metabolism of Conivaptan can be decreased when combined with Sertaconazole.Approved
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Conivaptan.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Conivaptan.Approved
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Conivaptan.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Conivaptan.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Conivaptan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Conivaptan.Approved
SiltuximabThe serum concentration of Conivaptan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Conivaptan.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Conivaptan.Approved
SinefunginThe metabolism of Conivaptan can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Conivaptan can be decreased when combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Conivaptan.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Conivaptan is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Conivaptan.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Conivaptan.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Conivaptan.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Conivaptan.Approved
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Conivaptan.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Conivaptan.Approved
St. John's WortThe serum concentration of Conivaptan can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Conivaptan can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Conivaptan is combined with Streptokinase.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Conivaptan.Approved, Investigational
SulconazoleThe metabolism of Conivaptan can be decreased when combined with Sulconazole.Approved
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Conivaptan.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Conivaptan.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Conivaptan.Approved
SulfisoxazoleThe metabolism of Conivaptan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Conivaptan.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Conivaptan.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Conivaptan.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Conivaptan.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Conivaptan.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Conivaptan.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Conivaptan.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Conivaptan.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Conivaptan.Approved
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Conivaptan.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Conivaptan.Experimental
TavaboroleThe metabolism of Conivaptan can be decreased when combined with Tavaborole.Approved
TelaprevirThe serum concentration of Conivaptan can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Conivaptan can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Conivaptan.Approved, Investigational
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Conivaptan.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Conivaptan.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Conivaptan.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Conivaptan.Approved
TerbinafineThe metabolism of Conivaptan can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Conivaptan can be decreased when combined with Terconazole.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Conivaptan.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Conivaptan.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Conivaptan.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Conivaptan.Approved, Vet Approved
ThalidomideThe risk or severity of adverse effects can be increased when Conivaptan is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Conivaptan.Approved
ThiamylalThiamylal may increase the hypotensive activities of Conivaptan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Conivaptan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Thioridazine.Approved
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Conivaptan.Approved
ThymolThe metabolism of Conivaptan can be decreased when combined with Thymol.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Conivaptan.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Conivaptan.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Conivaptan.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Conivaptan.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Conivaptan.Approved, Investigational
TioconazoleThe metabolism of Conivaptan can be decreased when combined with Tioconazole.Approved
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Conivaptan.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Conivaptan.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Conivaptan.Approved
TocilizumabThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Conivaptan.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe metabolism of Conivaptan can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Conivaptan.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Conivaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Conivaptan.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Conivaptan.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Conivaptan.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Conivaptan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Conivaptan.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Conivaptan is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Conivaptan.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Conivaptan.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Conivaptan.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Conivaptan.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Conivaptan.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Conivaptan.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Conivaptan.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Conivaptan.Approved, Vet Approved
TrimetrexateThe metabolism of Conivaptan can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Conivaptan.Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Conivaptan.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Conivaptan.Approved
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Conivaptan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Conivaptan.Approved
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Conivaptan.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Conivaptan.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Conivaptan.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Conivaptan.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Conivaptan.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Conivaptan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Conivaptan.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Conivaptan.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Conivaptan.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Conivaptan.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Conivaptan.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Conivaptan.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Conivaptan.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Conivaptan.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Conivaptan.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Conivaptan.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Conivaptan.Approved
VoriconazoleThe serum concentration of Conivaptan can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Conivaptan.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Conivaptan.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Conivaptan.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Conivaptan.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Conivaptan.Approved
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Conivaptan.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Conivaptan.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Conivaptan.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Conivaptan.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Conivaptan.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Conivaptan.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Conivaptan.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Conivaptan.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
  2. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
  3. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
External Links
ATC CodesC03XA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (145 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9522
Caco-2 permeable+0.5291
P-glycoprotein substrateSubstrate0.5919
P-glycoprotein inhibitor IInhibitor0.6901
P-glycoprotein inhibitor IIInhibitor0.8429
Renal organic cation transporterNon-inhibitor0.6631
CYP450 2C9 substrateNon-substrate0.7671
CYP450 2D6 substrateNon-substrate0.7534
CYP450 3A4 substrateSubstrate0.6602
CYP450 1A2 substrateInhibitor0.7008
CYP450 2C9 inhibitorInhibitor0.5368
CYP450 2D6 inhibitorNon-inhibitor0.6597
CYP450 2C19 inhibitorInhibitor0.8477
CYP450 3A4 inhibitorInhibitor0.9027
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9043
Ames testNon AMES toxic0.6672
CarcinogenicityNon-carcinogens0.8831
BiodegradationNot ready biodegradable0.9584
Rat acute toxicity2.5446 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Inhibitor0.8456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astellas pharma us inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous20 mg/100mL
Prices
Unit descriptionCostUnit
Vaprisol 20 mg/100 ml bag6.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5723606 No1999-12-152019-12-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble (0.15 mg/mL at 23 °C)Not Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00175 mg/mLALOGPS
logP5.23ALOGPS
logP5.44ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)11.14ChemAxon
pKa (Strongest Basic)6.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.09 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity150.83 m3·mol-1ChemAxon
Polarizability55.51 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • Biphenyl
  • Benzazepine
  • N-arylamide
  • Aminobenzoic acid or derivatives
  • Benzoic acid or derivatives
  • Benzoyl
  • Azepine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.
Gene Name:
AVPR1A
Uniprot ID:
P37288
Molecular Weight:
46799.105 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
  3. Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K: A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007 Jan;30(1):91-5. [PubMed:17202666 ]
  4. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95. [PubMed:17592003 ]
  5. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
  6. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7. [PubMed:16522696 ]
  7. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. [PubMed:19057376 ]
  8. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
  9. Ali F, Guglin M, Vaitkevicius P, Ghali JK: Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847-58. [PubMed:17428103 ]
  10. Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH: Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237. [PubMed:19663609 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name:
AVPR2
Uniprot ID:
P30518
Molecular Weight:
40278.57 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, Sasamata M, Miyata K: Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51. Epub 2005 Jan 1. [PubMed:15659304 ]
  3. Palm C, Pistrosch F, Herbrig K, Gross P: Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med. 2006 Jul;119(7 Suppl 1):S87-92. [PubMed:16843091 ]
  4. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
  5. Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K: A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007 Jan;30(1):91-5. [PubMed:17202666 ]
  6. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95. [PubMed:17592003 ]
  7. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
  8. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7. [PubMed:16522696 ]
  9. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. [PubMed:19057376 ]
  10. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
  11. Ali F, Guglin M, Vaitkevicius P, Ghali JK: Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847-58. [PubMed:17428103 ]
  12. Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH: Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237. [PubMed:19663609 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:42